Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2045-2322

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis ; volume:8 ; number:1 ; day:19 ; month:11 ; year:2018 ; pages:1 ; date:12.2018
Scientific reports ; 8, Heft 1 (19.11.2018), 1, 12.2018

Classification: Allgemeines, Wissenschaft

Creator: Passiglia, Francesco
Rizzo, Sergio
Di Maio, Massimo
Galvano, Antonio
Badalamenti, Giuseppe
Listì, Angela
Gulotta, Leonardo
Castiglia, Marta
Fulfaro, Fabio
Bazan, Viviana
Russo, Antonio

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41598-018-35524-y

URN: urn:nbn:de:101:1-2019010101553155967665

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:58 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Passiglia, Francesco
Rizzo, Sergio
Di Maio, Massimo
Galvano, Antonio
Badalamenti, Giuseppe
Listì, Angela
Gulotta, Leonardo
Castiglia, Marta
Fulfaro, Fabio
Bazan, Viviana
Russo, Antonio
SpringerLink (Online service)

Other Objects (12)

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Aufsatzsammlung

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis

EGFR exon 20 insertion mutations in NSCLC

Sulforaphane attenuates EGFR signaling in NSCLC cells

Predictive significance of circulating tumor DNA against patients with T790M-positive EGFR-mutant NSCLC receiving osimertinib

NSCLC – Neuer TKI zeigt Wirksamkeit bei EGFR-Resistenzmutation

Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC

Plasma metabolomics profiling of EGFR-mutant NSCLC patients treated with third-generation EGFR-TKI

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR

Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Brain metastasis, EGFR mutation subtype and generation of EGFR-TKI jointly influence the treatment outcome of patient with EGFR-mutant NSCLC

Related objects

Reset password